Overview

A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

A cross-over study, where ND0611 or placebo will be tested on top of 3 different LD/CD dosage forms. Safety and tolerability, pharmacokinetic profile of levodopa and carbidopa and the potential clinical effect of ND0611 will be explored in subjects with PD and motor fluctuations.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

NeuroDerm Ltd.

Treatments:

Carbidopa
Levodopa